Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608
Relay Therapeutics, Inc.
Relay Therapeutics Inc. (RLAY)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Commodore Capital Egen Atkinson And Michael Kramarz | 17,000,000 | $88,740,000 | +28% | 4.33% |
| 2. | Point72 Asset Management Steve Cohen | 14,773,676 | $77,118,589 | +10% | 0.13% |
| 3. | Casdin Capital Eli Casdin | 11,341,381 | $59,202,009 | -1% | 4.94% |
| 4. | Tang Capital Management Kevin C. Tang | 8,068,058 | $42,115,263 | 1.62% | |
| 5. | Kynam Capital Derrick Tang | 2,887,014 | $15,070,213 | 1.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 403,082 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 1,021,952 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 10,000 | $200,000.00 | 10,000 | 2020-07-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.00 | 62,073 | $434,511.00 | 703,215 | 2025-11-03 | Filing | |
| $7.50 | 21,394 | $160,455.00 | 337,469 | 2025-10-29 | Filing | |
| $7.29 | 19,135 | $139,494.15 | 358,863 | 2025-10-28 | Filing | |
| $7.29 | 21,664 | $157,930.56 | 313,631 | 2025-10-28 | Filing | |
| $7.29 | 30,897 | $225,239.13 | 521,823 | 2025-10-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,904,963 | $145,663,907 | 1.1% | |
| 2. | 13,759,382 | $71,823,974 | 0% | |
| 3. | 9,395,744 | $49,045,785 | 0% | |
| 4. | 8,345,610 | $43,564,084 | 0.91% | |
| 5. | 5,065,990 | $26,444,468 | 0% |
News See All
Top 10 AI-Powered Biotech Stocks to Buy Now
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC's "Squawk Box" on July 25 to discuss a variety of topics, including the status of the biotech industry and what to...
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
Leerink Partners Reiterates a Buy Rating on Relay Therapeutics (RLAY) With a $12 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the top strong buy stocks under $5 to buy now. Leerink Partners analyst Andrew Berens reiterated a Buy rating on Relay Therapeutics, Inc.
15 Strong Buy Stocks Under $5 to Buy Now
On August 22, Tom Lee, head of research and chief investment officer of Fundstrat Capital, appeared on CNBC’s ‘Squawk on the Street’ to talk about what he thinks about Fed Chair Powell’s speech...
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Barclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best strong buy penny stocks to buy now.
10 Best Strong Buy Penny Stocks to Buy Now
On July 28, Alan Rechtschaffen, UBS Global Wealth senior portfolio manager, appeared on CNBC’s ‘Money Movers’ to talk about the markets, his Fed outlook, and more.
Barclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best biotech penny stocks to buy right now.
Hedge Fund Resource Center Billionaire Hedge Funds
